CHARM Alternative trial

Last reviewed 01/2018

The CHARM-Alternative trial recruited 2028 ACE inhibitor-intolerant patients with heart failure due to left ventricular dysfunction. The patients were randomised to either candesartan or placebo.

Treatment with candesartan (an angiotensin receptor antagonist) gave clear reductions in mortality and hospital admissions.

Reference:

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386):772-6.